What Is Heparin-Binding EGF-Like Growth Factor? Definition and What Research Reports

Definition

Heparin-binding EGF-like growth factor (HB-EGF) is a member of the epidermal growth factor (EGF) family of signalling proteins. It is produced first as a membrane-anchored precursor (proHB-EGF) that can be cleaved by cell-surface proteases to release a soluble, heparin-binding form; both forms interact with ErbB-family (EGF) receptors, and the heparin-binding region allows the protein to associate with heparan sulfate proteoglycans in the extracellular matrix. In the research literature the term refers to the endogenous human or animal protein and to the recombinant protein used as a laboratory reagent in cell culture and animal models. It is a growth factor, not a short synthetic peptide, and in the United States recombinant HB-EGF is handled as a research-use-only material rather than an approved drug product. This page is for educational purposes only and is not medical advice; consult a licensed physician with any question about a medical condition or treatment.

What Class of Molecule It Is and Where It Comes From

HB-EGF belongs to the same ligand family as EGF, transforming growth factor-alpha and amphiregulin. Rather than being synthesised chemically like many research peptides, it is expressed by cells — including epithelial cells, smooth muscle cells, macrophages and placental tissue — and is found in biological fluids. A 2002 study reported that HB-EGF was present in human amniotic fluid and in breast milk, which framed later interest in its role in the developing gut (PMID 11781977). A 2020 study characterised placental heparin-binding epidermal growth factor-like growth factor in the baboon, extending the description of the protein to a non-human primate model of pregnancy (PMID 32272450).

Naming and abbreviations

• HB-EGF — the standard abbreviation used across the literature.
• proHB-EGF — the membrane-anchored precursor before proteolytic shedding.
• Heparin-binding epidermal growth factor-like growth factor — the fully written form, used in some journals, as in the baboon placental study (PMID 32272450).

How the Term Is Used in Peptide and Growth Factor Research

In laboratory writing, "HB-EGF" usually appears in one of three contexts: as an endogenous signal whose expression is measured in a tissue; as a recombinant protein applied to cells or administered to animals in an experimental model; or as a target that is blocked or silenced to test what happens when the signal is removed. That third usage appeared in a 2019 study in which researchers used an HB-EGF antisense oligonucleotide and reported protection against hyperlipidemia-associated atherosclerosis in an animal model (PMID 30738642). Because HB-EGF acts on EGF receptors, papers frequently discuss it alongside ErbB receptor signalling rather than in isolation.

What the Published Literature Reports

Intestinal injury and the enteric nervous system

A 2014 review summarised the application of HB-EGF therapy for intestinal injury and discussed future prospects for that line of work, positioning the protein as an experimental agent in models of gut damage rather than an established treatment (PMID 24345808). A 2017 study reported that HB-EGF promoted neuronal nitric oxide synthase expression and protected the enteric nervous system after necrotizing enterocolitis in an experimental model (PMID 28422949).

Cell migration, adhesion and wound repair

A 2014 study reported that HB-EGF promoted cell migration and adhesion through focal adhesion kinase signalling in cultured cells (PMID 24703506). Earlier, a 2005 study reported that HB-EGF accelerated keratinocyte migration and skin wound healing, linking the growth factor to re-epithelialisation of cutaneous wounds (PMID 15923649). These two papers are the ones most often cited when the literature describes HB-EGF as a "motogenic" or migration-promoting factor.

Heart, lung and brain

A 2003 study concluded that HB-EGF and ErbB signalling were essential for heart function, based on genetic work in mice (PMID 12621152). In the lung, a 2018 study reported that HB-EGF attenuated lung inflammation and injury in a murine model of pulmonary emphysema (PMID 30600734). In the nervous system, a 2011 study reported that HB-EGF was required for synaptic plasticity and memory formation (PMID 21945083).

Bone cell differentiation and cancer biology

A 2013 study reported that HB-EGF and miR-1192 exerted opposite effects on Runx2-induced osteogenic differentiation, describing HB-EGF as one arm of a regulatory pair in bone-forming cells (PMID 24136232). A separate 2013 study reported that HB-EGF enhanced invasion and metastasis activity in thyroid cancer cells, which is an example of the growth-promoting properties of EGF-family ligands being reported in a tumour context (PMID 23917679).

Summary Table of Cited Research Contexts

Safety and Tolerability: What Studies Report

The verified literature summarised here consists of cell-culture work, animal models and a review of experimental intestinal applications; none of these papers is presented as a human safety or tolerability trial, and no dosing schedule for people is described in them. The clearest caution raised within the published work itself is biological rather than toxicological: because HB-EGF signals through EGF receptors, a 2013 study reported that it enhanced invasion and metastasis activity in thyroid cancer cells (PMID 23917679), while a 2019 study reported that suppressing HB-EGF with an antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis in an animal model (PMID 30738642). Taken together, the studies describe a signal whose effects depend heavily on tissue and context, which is why the 2014 review framed intestinal HB-EGF work as a prospect for further research (PMID 24345808). This entry is definitional and does not describe any protocol; anyone with a clinical question should raise it with a licensed physician.

Related Terms

• EGF family — the ligand group that includes HB-EGF, EGF, TGF-alpha and amphiregulin.
• ErbB receptors — the receptor family through which HB-EGF signals, described as essential for heart function alongside HB-EGF in a 2003 study (PMID 12621152).
• Focal adhesion kinase (FAK) — an intracellular kinase reported to mediate HB-EGF-driven migration and adhesion (PMID 24703506).
• Runx2 — the transcription factor whose osteogenic activity was examined together with HB-EGF and miR-1192 (PMID 24136232).

References

• Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects (Pathophysiology, 2014)
• Heparin-binding EGF-like growth factor is required for synaptic plasticity and memory formation (Brain Research, 2011)
• Heparin-binding EGF-like growth factor promotes neuronal nitric oxide synthase expression and protects the enteric nervous system after necrotizing enterocolitis (Pediatric Research, 2017)
• Heparin-binding EGF-like growth factor (HB-EGF) promotes cell migration and adhesion via focal adhesion kinase (Journal of Surgical Research, 2014)
• Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing (Journal of Cell Science, 2005)
• Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function (PNAS, 2003)
• Baboon placental heparin-binding epidermal growth factor-like growth factor (Reproduction, 2020)
• Heparin-binding EGF-like growth factor attenuates lung inflammation and injury in a murine model of pulmonary emphysema (Growth Factors, 2018)
• Heparin-binding EGF-like growth factor and miR-1192 exert opposite effect on Runx2-induced osteogenic differentiation (Cell Death & Disease, 2013)
• Heparin-binding EGF-like growth factor (HB-EGF) antisense oligonucleotide protected against hyperlipidemia-associated atherosclerosis (NMCD, 2019)
• Heparin-binding EGF-like growth factor is present in human amniotic fluid and breast milk (Journal of Pediatric Surgery, 2002)
• Heparin-binding EGF-like growth factor enhances the activity of invasion and metastasis in thyroid cancer cells (Oncology Reports, 2013)